Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy

T memory stem cells (T-SCM) display increased self-renewal and prolonged survival capabilities, thus preventing T cell exhaustion and promoting effective anti-tumor T cell responses. T-SCM cells can be expanded by Urolithin A (UA), which is produced by the commensal gut microbiome from foods rich in ellagitannins and is known to improve mitochondrial health. Oral UA administration to tumor-bearing mice conferred strong anti-tumor CD8(+) T cell immunity, whereas ex vivo UA pre-treated T cells displayed improved anti-tumor function upon adoptive cell transfer. UA-induced T-SCM formation depended on Pink1-mediated mitophagy triggering cytosolic release of the mitochondrial phosphatase Pgam5. Cytosolic Pgam5 dephosphorylated beta-catenin, which drove Wnt signaling and compensatory mitochondrial biogenesis. Collectively, we unravel a critical signaling pathway linking mitophagy to T-SCM formation and suggest that the well-tolerated metabolic compound UA represents an attractive option to improve immune therapy.

Automated summary

T memory stem cells (T-SCM) can be expanded by UA and oral administration of UA enhances anti-tumor CD8(+) T cell immunity. The formation of T-SCM cells induced by UA depends on Pink1-mediated mitophagy triggering cytosolic release of Pgam5, which drives Wnt signaling and compensatory mitochondrial biogenesis.